Shares of AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $37.50.
AGMB has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Cantor Fitzgerald assumed coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. Piper Sandler started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price on the stock. B. Riley Financial initiated coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. Finally, Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th.
Check Out Our Latest Stock Analysis on AgomAb Therapeutics
AgomAb Therapeutics Trading Down 1.0%
AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, equities research analysts forecast that AgomAb Therapeutics will post -1.76 earnings per share for the current fiscal year.
About AgomAb Therapeutics
AgomAb Therapeutics N.V. (NASDAQ: AGMB) is a clinical-stage biopharmaceutical company developing medicines for diseases involving tissue damage, fibrosis and impaired regeneration. The company’s approach includes modulating biological pathways that influence tissue repair and remodeling, with the goal of addressing conditions with significant unmet medical needs.
AgomAb’s lead clinical program is AGMB-129, an oral, gut-restricted inhibitor of activin receptor-like kinase 5 (ALK5), a receptor involved in transforming growth factor beta signaling.
Featured Stories
- Five stocks we like better than AgomAb Therapeutics
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
